AU2018311976B2 - Inhibitors of Plasma Kallikrein and uses thereof - Google Patents

Inhibitors of Plasma Kallikrein and uses thereof Download PDF

Info

Publication number
AU2018311976B2
AU2018311976B2 AU2018311976A AU2018311976A AU2018311976B2 AU 2018311976 B2 AU2018311976 B2 AU 2018311976B2 AU 2018311976 A AU2018311976 A AU 2018311976A AU 2018311976 A AU2018311976 A AU 2018311976A AU 2018311976 B2 AU2018311976 B2 AU 2018311976B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
thiazole
amino
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018311976A
Other languages
English (en)
Other versions
AU2018311976A1 (en
Inventor
Thomas Miller
Nikolaos PAPAIOANNOU
Jeremy Travins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2018311976A1 publication Critical patent/AU2018311976A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: DYAX CORP.
Application granted granted Critical
Publication of AU2018311976B2 publication Critical patent/AU2018311976B2/en
Priority to AU2023200156A priority Critical patent/AU2023200156B2/en
Priority to AU2025204840A priority patent/AU2025204840A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018311976A 2017-08-04 2018-08-03 Inhibitors of Plasma Kallikrein and uses thereof Active AU2018311976B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023200156A AU2023200156B2 (en) 2017-08-04 2023-01-12 Inhibitors of plasma Kallikrein and uses thereof
AU2025204840A AU2025204840A1 (en) 2017-08-04 2025-06-26 Inhibitors of plasma Kallikrein and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541403P 2017-08-04 2017-08-04
US62/541,403 2017-08-04
PCT/US2018/045183 WO2019028362A1 (en) 2017-08-04 2018-08-03 INHIBITORS OF PLASMATIC KALLIKREIN AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200156A Division AU2023200156B2 (en) 2017-08-04 2023-01-12 Inhibitors of plasma Kallikrein and uses thereof

Publications (2)

Publication Number Publication Date
AU2018311976A1 AU2018311976A1 (en) 2020-02-06
AU2018311976B2 true AU2018311976B2 (en) 2022-10-13

Family

ID=63209746

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018311976A Active AU2018311976B2 (en) 2017-08-04 2018-08-03 Inhibitors of Plasma Kallikrein and uses thereof
AU2023200156A Active AU2023200156B2 (en) 2017-08-04 2023-01-12 Inhibitors of plasma Kallikrein and uses thereof
AU2025204840A Pending AU2025204840A1 (en) 2017-08-04 2025-06-26 Inhibitors of plasma Kallikrein and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023200156A Active AU2023200156B2 (en) 2017-08-04 2023-01-12 Inhibitors of plasma Kallikrein and uses thereof
AU2025204840A Pending AU2025204840A1 (en) 2017-08-04 2025-06-26 Inhibitors of plasma Kallikrein and uses thereof

Country Status (6)

Country Link
US (3) US11168083B2 (enExample)
EP (2) EP4494698A3 (enExample)
JP (3) JP7210540B2 (enExample)
AU (3) AU2018311976B2 (enExample)
CA (1) CA3070717A1 (enExample)
WO (1) WO2019028362A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4494698A3 (en) 2017-08-04 2025-04-23 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
CN112135825A (zh) 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
ES2987744T3 (es) 2019-09-18 2024-11-18 Takeda Pharmaceuticals Co Inhibidores de calicreína plasmática y usos de los mismos
JP7695232B2 (ja) 2019-09-18 2025-06-18 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター
JP2023510854A (ja) * 2020-01-13 2023-03-15 武田薬品工業株式会社 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
JP2025531207A (ja) * 2022-09-15 2025-09-19 武田薬品工業株式会社 遺伝性血管性浮腫の処置のための血漿カリクレイン阻害剤としてのｎ－（（イソキノリン－６イル）メチル）－１ｈ－ピラゾール－４－カルボキサミド誘導体
CN116063215A (zh) * 2023-02-23 2023-05-05 南京安淮创新药物研究院有限公司 一种4-氨基-l-脯氨酸的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508033A (en) 1998-06-30 2002-12-20 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
PL1966130T3 (pl) * 2005-12-23 2014-05-30 Zealand Pharma As Zmodyfikowane związki mimetyczne lizyny
WO2010015090A1 (en) * 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
BR112014015582A8 (pt) * 2012-02-24 2017-07-04 Hoffmann La Roche compostos antivirais
GB201209138D0 (en) * 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
JP6337750B2 (ja) * 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
SI3261639T1 (sl) * 2015-02-27 2023-01-31 Verseon International Corporation Substituirane pirazolne spojine kot zaviralci serinskih proteaz
BR112017020864A2 (en) 2015-03-30 2018-07-10 Dyax Corp. plasma kallikrein inhibitors and their uses for the prevention of hereditary angioedema attack
US20190263818A1 (en) * 2015-07-01 2019-08-29 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EA038492B1 (ru) * 2015-10-01 2021-09-07 Байокрист Фармасьютикалз, Инк. Ингибиторы плазменного калликреина человека
EP4494698A3 (en) 2017-08-04 2025-04-23 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
JP7695232B2 (ja) * 2019-09-18 2025-06-18 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター
ES2987744T3 (es) * 2019-09-18 2024-11-18 Takeda Pharmaceuticals Co Inhibidores de calicreína plasmática y usos de los mismos
ES3035604T3 (en) * 2020-04-17 2025-09-05 Takeda Pharmaceuticals Co Forms and compositions of inhibitors of plasma kallikrein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gardelli, C. et al, Journal of Medicinal Chemistry, 2007, 50(20), 4953-75 *

Also Published As

Publication number Publication date
JP2024045291A (ja) 2024-04-02
JP2023040213A (ja) 2023-03-22
EP4494698A3 (en) 2025-04-23
JP7785108B2 (ja) 2025-12-12
JP7210540B2 (ja) 2023-01-23
AU2018311976A1 (en) 2020-02-06
AU2025204840A1 (en) 2025-07-17
EP3661922A1 (en) 2020-06-10
AU2023200156A1 (en) 2023-02-09
EP4494698A2 (en) 2025-01-22
JP7427812B2 (ja) 2024-02-05
US20200239463A1 (en) 2020-07-30
US11905285B2 (en) 2024-02-20
US20240199602A1 (en) 2024-06-20
AU2023200156B2 (en) 2025-04-24
JP2020529998A (ja) 2020-10-15
US20220056028A1 (en) 2022-02-24
EP3661922B1 (en) 2024-10-23
WO2019028362A1 (en) 2019-02-07
US11168083B2 (en) 2021-11-09
CA3070717A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
AU2023200156B2 (en) Inhibitors of plasma Kallikrein and uses thereof
EP3652329B1 (en) Compounds for tau protein degradation
AU2017363307B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
CA3042731A1 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
AU2018342105B2 (en) Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
EP3876939A1 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
KR20220098732A (ko) 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체
CA3218259A1 (en) Small molecule modulators of glucocerebrosidase activity and uses thereof
KR20250109229A (ko) Ripk2 억제제 및 이의 용도
AU2018215089C1 (en) Anti-fibrotic compounds
KR20220110744A (ko) 암 줄기 세포를 표적화하는 암 치료
CA3218510A1 (en) Small molecule modulators of glucocerebrosidase activity and uses thereof
HK40123072A (en) Inhibitors of plasma kallikrein and uses thereof
HK40029252A (en) Inhibitors of plasma kallikrein and uses thereof
HK40029252B (en) Inhibitors of plasma kallikrein and uses thereof
HK40106846A (en) Compounds for tau protein degradation

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): DYAX CORP.

FGA Letters patent sealed or granted (standard patent)